drugset / Trial / NCT02391805
A Study of Treatment With RO6864018 in Virologically Suppressed Participants With Chronic Hepatitis B Virus (HBV) Infection
RandomizedParallel-groupDouble-blindTreatment
Summary
This randomized, multicenter, partially double-blind, placebo-controlled study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antiviral effects of treatment with RO6864018 in virologically suppressed participants with chronic HBV infection.
Timeline
- Start
- 2015-05-17
- Primary completion
- 2017-10-16
- Completion
- 2017-10-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RO6864018 | Unknown | 800 mg | Oral |
| Subject | RO6864018 | Unknown | 1200 mg | Oral |
| Background | Entecavir | Small molecule | — | — |
| Background | Tenofovir | Small molecule | — | — |